On April 24, the 3rd meeting of the 6th Board of Directors of DC PHARMA approved the " Proposal on Introducing Investors to the holding subsidiary for Capital Increase and Share Expansion ". It was agreed that Yantai Lannacheng Biotechnology Co., Ltd., as the holding subsidiary of DC PHARMA, would introduce investors in the way of capital increase and share expansion. Shenzhen Capital Group Co.,Ltd led the investment, and followed by Qianyanfangzhou, Yantai Caijing, Longxin Tongzi, Aohua Qingjie Nengyuan. This B+ financing successfully raised a total of RMB 300 million with a pre-investment valuation of RMB 1.95 billion.

Recently, LNC PHARMA received the ⁶⁸Ga-LNC1007 FDA (Food and Drug Administration) IND approval, and will conduct Phase I clinical trial in the near future.

Recently, LNC received the EC (Ethics Committee) approval from the Beijing Hospital regarding the 18F-LNC1001 Injection and will conduct the Phase III clinical trial in the near future.

Recently, LNC received the 177Lu-LNC1003 Injection IND approval from the NMPA (National Medical Products Administration), and will conduct the Phase I clinical trial in the near future.

Recently, LNC PHARMA received the IND approval for the 177Lu-LNC1003 Injection from the HSA (Health Sciences Authority), and will conduct the Phase I clinical trial in the near future.

Before then, 177Lu-LNC1003 injection has also obtained the IND approval from the US FDA (Food and Drug Administration) on Apr. 2023.

On Oct. 20-22, the 5th International Molecular Imaging Symposium (IMIS 2023)- the Xiamen University, also known as the Innovative Radiopharmaceutical Development and Clinical Transformation Seminar were held grandly. As an influential and leading event in the field of molecular imaging, this forum brings together more than 500 industry elites, including academicians, experts, physicians, and entrepreneurs, to deliver keynote speeches, participate in professional conferences, and discuss the development direction of molecular imaging.

Dongcheng International Pharmaceutical Innovation Application Base project is important for the Group to promote the future development of the nuclear medicine. Since the start of the project, it has made rapid progress and has received widespread attention and expectations from all sectors. Recently, “Yantai News” focused on the construction of the Blue Medicine Valley Life Island project and provided a detailed introduction to the LNC innovative drugs.

Recently, at the European Association of Nuclear Medicine 36th Annual Congress (EANM2023, Sept. 9-13th, 2023), Vienna, Austria, LNC once again introduced its innovative research achievements in the field of radionuclide diagnosis and treatment, which obtained great attention and recognition from international peers.